CoChat
Sign Up
Cited by 243Multiple Sclerosis Research StudiesCancer survivorship and careFibromyalgia and Chronic Fatigue Syndrome Research

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey

Open access
Hadjimichael, Olympia, Vollmer, Timothy, Oleen-Burkey, MerriKay·2008·Health and Quality of Life Outcomes
DOI 10.1186/1477-7525-6-100PMC PMC2596785
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Fatigue is a common disabling symptom of multiple sclerosis (MS) and has a significantly negative impact on quality of life. Persons with MS enrolled in the North American Research Committee on Multiple Sclerosis (NARCOMS) Patient Registry are invited to complete follow-up surveys every six months to update their original registration information. One of these surveys was designed to focus on the severity and impact of fatigue, and its association with other clinical parameters of MS such as physical disability. Methods: In addition to the usual data collected in Registry update surveys such as demographic characteristics, MS-related medical history, disability and handicap, immunomodulatory and symptomatic therapies taken, and healthcare services used, the survey for this study included two validated self-report fatigue scales, the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS) and questions about the use of symptomatic management for fatigue, both pharmacologic and non-pharmacologic treatments. This Registry update survey was mailed to all NARCOMS registrants (n = 18,595) in November 2002. Information provided by registry participants was approved for research purposes by the Yale University Institutional Review Board. Results: The response rate for the survey was 49.5% (9205/18,595). Severe fatigue as measured with the FSS using the developer's recommended severity cutpoint of ≥ 36 was reported by 6691 (74%) of evaluable respondents (n = 9077). A higher prevalence of severe fatigue was observed in relapsing-worsening MS compared with relapsing-stable and primary progressive MS. A distinct pattern of fatigue was observed across the disability levels of the Patient-Determined Disease Steps (PDDS). Although there were no differences in the severity or impact of fatigue by immunomodulatory agents (IMA), respondents who recalled therapy changes in the prior six months reported different patterns of change in fatigue with lower fatigue levels reported after changing from interferon-β to glatiramer acetate than after changing from glatiramer acetate to interferon-β. Concomitant therapy for fatigue was used by 47.2% of the 5799 survey respondents receiving IMA. Conclusion: Characterizing MS symptoms like fatigue can increase awareness about their impact on persons with MS and suggest recommendations for a care plan.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1477-7525-6-100

Cites

51 of 52 references verified1 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Fatigue by PDDS levels. FSS, Fatigue Severity Scale; MFIS, Modified Fatigue Impact Scale; PDDS, Patient-Determined Disease Steps.
Figure 1 Fatigue by PDDS levels. FSS, Fatigue Severity Scale; MFIS, Modified Fatigue Impact Scale; PDDS, Patient-Determined Disease Steps.CC BY · PubMed Central
Figure 2 Changes in fatigue rating following a change in IMA. NARCOMS respondents who changed from IFN to GA (n = 766) and from GA to IFN (n = 218). IFN, Interferon β-1a or 1b; GA, glatiramer acetate; IMA, immunomodulatory agents.
Figure 2 Changes in fatigue rating following a change in IMA. NARCOMS respondents who changed from IFN to GA (n = 766) and from GA to IFN (n = 218). IFN, Interferon β-1a or 1b; GA, glatiramer acetate; IMA, immunomodulatory agents.CC BY · PubMed Central
Figure 3 Current use of symptomatic treatments for fatigue based on the use of IMA. IMA = NARCOMS respondents treated with IMA;No IMA = NARCOMS respondents not treated with IMAs. 4-AP, 4-aminopyridine; IMA, immunomodulatory agents.
Figure 3 Current use of symptomatic treatments for fatigue based on the use of IMA. IMA = NARCOMS respondents treated with IMA;No IMA = NARCOMS respondents not treated with IMAs. 4-AP, 4-aminopyridine; IMA, immunomodulatory agents.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 2

  1. Multiple Sclerosis Clinical Practice Guidelines Council: Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. In Multiple sclerosis clinical practice guideline. Washington, DC: Paralyzed Veterans Association; 1998.
  2. Edgely K, Sullivan MJL, Dehoux E: A survey of multiple sclerosis: Pt 2: determinations of employment status. Can J Rehab 1991, 4: 127–132.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Hadjimichael, O., Vollmer, T., & Oleen-Burkey, M.
Affiliations
  • Yale University (US)
  • Barrow Neurological Institute (US)
Corresponding author
Oleen-Burkey, MerriKay
ORCID
Vollmer, Timothy
Venue
Health and Quality of Life Outcomes
Publisher
Springer Science and Business Media LLC
Published
2008-11-14
Volume
6
Issue
1
Pages
100-100
ISSN
1477-7525 (ISSN-L)
DOI
10.1186/1477-7525-6-100
PMC
PMC2596785
OpenAlex
W2017544610
Cited by
240
References
52
Citations by year
2026: 5 · 2025: 9 · 2024: 8 · 2023: 10 · 2022: 15 · 2021: 21 · 2020: 14 · 2019: 10 · 2018: 19 · 2017: 15 · 2016: 12 · 2015: 19 · 2014: 19 · 2013: 17 · 2012: 10
FWCI
8.54
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Health and Quality of Life Outcomes (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Yale University
  • Teva Pharmaceutical Industries
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
Keywords
multiple sclerosis, fatigue, Fatigue Severity Scale, Modified Fatigue Impact Scale, primary progressive multiple sclerosis, disability severity, Patient-Determined Disease Steps, interferon-beta, glatiramer acetate, immunomodulatory therapy, quality of life
MeSH terms
Glatiramer Acetate, Adult, Chronic Disease, Fatigue, Female, Humans, Immunologic Factors, Immunosuppressive Agents, Male, Middle Aged, Multiple Sclerosis, Muscle Spasticity, North America, Pain Measurement, Peptides, Psychometrics, Quality of Life, Surveys and Questionnaires, Registries, Severity of Illness Index, Prevalence, Treatment Outcome, Interferon-beta, Sickness Impact Profile, Disease Progression, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review